CO-OPTIV-SECURIT
10.6.2019 15:07:06 CEST | Business Wire | Press release
Optiv Security , a global cybersecurity integrator delivering end-to-end cybersecurity solutions, today announced it has been recognized by Forrester Research as a Strong Performer in The Forrester WaveTM : Global Cybersecurity Consulting Providers, Q2 2019. The report identifies Optiv as having received the highest possible score for six criteria:
- Delivery and engagement innovation
- IP and asset-based consulting
- Technical consulting and assessment capabilities
- Cybersecurity focus
- Go-to-market strategy
- Partnership ecosystems
“Optiv’s approach to cybersecurity is aligned to new business models and centered on driving client-focused outcomes. It is designed to optimize and rationalize existing cybersecurity programs, build new integrated, end to end cybersecurity programs, and help clients transform how they are consuming and applying cybersecurity,” said Bryan Wiese, division vice president, global advisory services for Optiv.
“We believe that receiving this designation from Forrester as a Strong Performer affirms our approach to consulting for global enterprises,” continued Wiese. “Historically, the fear of external threats and vulnerabilities has often guided clients’ security initiatives. That fear has sometimes led to tactical investment, too much of a focus on technology, and siloed problem solving. At Optiv we work with clients to manage their security programs from the ‘inside-out,’ starting with risk mitigation and building from there with customized strategy, focused process definition, technology rationalization and operations optimization, ongoing measurement and communication. Our approach is specifically designed to deliver to organizations integrated cybersecurity solutions that address the speed of business change by providing new consumption and outcome-based consulting services and cybersecurity solutions. Our goal is help clients strike the right balance between risk mitigation, business alignment, and cost.”
Optiv’s full suite of advisory services can be consumed alone or combined with Optiv’s integration or managed services, or Cyber-as-a-Service (CaaSTM ) platform to harden security fundamentals across six main domains:
- Risk Management and Transformation – Optiv enables clients to address risk and regulatory changes with an inside-out strategy that begins with business needs and applies strategy, technology and processes to effectively manage risk and enable cyber resilience.
- Cyber Operations – Optiv helps clients strike the right balance of people, process, technologies and delivery methods in order to elevate threat preparedness while aligning business goals and operational resilience and producing measurable outcomes at reduced operational costs.
- Cyber Digital Transformation – Optiv aligns client business needs with a security-by-design approach that employs big data analytics, IoT, cloud, orchestration and automation and additional technology innovations to connect agile processes and controls.
- Identity and Data Management – Optiv helps clients tackle identity and data sprawl and exposure with comprehensive, strategic identity and data management solutions. Enabling organizations to quickly and securely provide access to the right company assets on- and off-premise ensures trust and compliance in the business while also strengthening security by classifying, governing and protecting sensitive data.
- Threat Management – Proactively solving threat management requires a comprehensive program that includes tracking technological and regulatory changes, driving security into network design and software development lifecycles, continual threat modeling, testing and remediation, an understanding of the attack surface, and readiness exercises to practice muscle memory and robust response should an incident occur.
Please visit Optiv’s website to learn more about Optiv’s cybersecurity consulting services .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: www.youtube.com/c/OptivInc
Blog: www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv is a global cybersecurity
solutions integrator – a “one-stop” trusted partner with a singular
focus on cybersecurity. Our end-to-end cybersecurity capabilities span
risk management and transformation, cyber digital transformation, threat
management, cyber operations, identity and data management, and
integration and innovation, helping organizations realize stronger,
simpler and more cost-efficient cybersecurity programs that support
business requirements and outcomes. At Optiv, we are modernizing
cybersecurity to enable clients to innovate their consumption models,
integrate infrastructure and technology to maximize value, achieve
measurable outcomes, and realize complete solutions and business
alignment. For more information about Optiv, please visit us at www.optiv.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005093/en/
Contact:
Brett Ater (913) 304-7683 brett.ater@optiv.com or Jason Cook (816) 701-3374 jason.cook@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
